Last reviewed · How we verify
Enoxaparin placebo syringe
This is a placebo syringe formulation used as a control in clinical trials; it contains no active pharmaceutical ingredient.
This is a placebo syringe formulation used as a control in clinical trials; it contains no active pharmaceutical ingredient. Used for Clinical trial control comparator for enoxaparin studies (not a therapeutic product).
At a glance
| Generic name | Enoxaparin placebo syringe |
|---|---|
| Sponsor | Beijing Anzhen Hospital |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Enoxaparin placebo syringe is an inert comparator product designed for blinded clinical studies evaluating enoxaparin (a low-molecular-weight heparin anticoagulant). The placebo mimics the appearance and administration route of active enoxaparin but delivers no therapeutic effect, allowing researchers to isolate the true efficacy of the active drug from placebo response.
Approved indications
- Clinical trial control comparator for enoxaparin studies (not a therapeutic product)
Common side effects
Key clinical trials
- Comparison of Anticoagulation Prolongation vs. no Anticoagulation in STEMI Patients After Primary PCI (PHASE4)
- The SYMPTOMS - SYstematic Elderly Medical Patients Thromboprophylaxis: Efficacy on Symptomatic OutcoMeS - Study (PHASE3)
- Low-Dose Tenecteplase in Covid-19 Diagnosed With Pulmonary Embolism (PHASE4)
- A Study Comparing the Local Tolerability of Two Subcutaneous Heparins in Healthy Volunteers. (PHASE4)
- PROphylaxis in NOn Major Orthopaedic Surgery (PHASE3)
- Clinical Study Assessing Idrabiotaparinux Sodium Injections Once-weekly in Pulmonary Embolism Therapeutic Approach (PHASE3)
- Study of Apixaban for the Prevention of Thrombosis-related Events Following Knee Replacement Surgery (PHASE3)
- Study of Apixaban for the Prevention of Thrombosis-related Events in Patients With Acute Medical Illness (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Enoxaparin placebo syringe CI brief — competitive landscape report
- Enoxaparin placebo syringe updates RSS · CI watch RSS
- Beijing Anzhen Hospital portfolio CI